Isocitrate Dehydrogenase (IDH1) inhibitors - Pipeline Insights, 2017

  • ID: 4037989
  • Drug Pipelines
  • 60 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
“Isocitrate Dehydrogenase (IDH1) inhibitors - Pipeline Insights, 2017” provides in depth insights on the pipeline drugs and their development activities around the Isocitrate Dehydrogenase (IDH1) inhibitors. The This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Isocitrate Dehydrogenase (IDH1) inhibitors. This report also assesses the Isocitrate Dehydrogenase (IDH1) inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please Note: This report requires certain updates. We have all the information available but require 2 business days to complete the process and ensure it is as up - to - date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope:
  • The report provides competitive pipeline landscape of Isocitrate Dehydrogenase (IDH1) inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Isocitrate Dehydrogenase (IDH1) inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Isocitrate Dehydrogenase (IDH1) inhibitors and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Delivery Time: 2 Working Days.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  1. Isocitrate Dehydrogenase (IDH1) inhibitors Overview
  2. Isocitrate Dehydrogenase (IDH1) inhibitors Disease Associated
  3. Isocitrate Dehydrogenase (IDH1) inhibitors Pipeline Therapeutics
  4. Isocitrate Dehydrogenase (IDH1) inhibitors Therapeutics under Development by Companies
  5. Isocitrate Dehydrogenase (IDH1) inhibitors Filed and Phase III Products
  6. Comparative Analysis
  7. Isocitrate Dehydrogenase (IDH1) inhibitors Phase II Products
  8. Comparative Analysis
  9. Isocitrate Dehydrogenase (IDH1) inhibitors Phase I and IND Filed Products
  10. Comparative Analysis
  11. Isocitrate Dehydrogenase (IDH1) inhibitors Discovery and Pre-Clinical Stage Products
  12. Comparative Analysis
  13. Drug Candidate Profiles
  14. Isocitrate Dehydrogenase (IDH1) inhibitors - Therapeutics Assessment
  15. Assessment by Monotherapy Products
  16. Assessment by Combination Products
  17. Assessment by Route of Administration
  18. Assessment by Molecule Type
  19. Isocitrate Dehydrogenase (IDH1) inhibitors - Discontinued Products
  20. Isocitrate Dehydrogenase (IDH1) inhibitors - Dormant Products
  21. Companies Involved in Therapeutics Development for Isocitrate Dehydrogenase (IDH1) inhibitors
  22. Appendix
  23. Methodology
  24. Contact Us
  25. Disclaimer
List of Tables
  1. Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors by Therapy Area, 2017
  2. Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors, 2017
  3. Number of Products under Development by Companies
  4. Comparative Analysis by Filed and Phase III Products, 2017
  5. Comparative Analysis Phase II Products, 2017
  6. Comparative Analysis Phase I and IND Filed Products, 2017
  7. Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
  8. Drug Candidates Profiles
  9. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Monotherapy Products
  10. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Combination Products
  11. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Route of Administration
  12. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Route of Administration
  13. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Molecule Type
  14. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Molecule Type
  15. Isocitrate Dehydrogenase (IDH1) inhibitors Therapeutics - Discontinued Products
  16. Isocitrate Dehydrogenase (IDH1) inhibitors Therapeutics - Dormant Products
  17. Products under Development by Companies, 2017
List of Figures
  1. Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors by Therapy Area, 2017
  2. Number of Products under Development for Isocitrate Dehydrogenase (IDH1) inhibitors, 2017
  3. Filed and Phase III Products, 2017
  4. Phase II Products, 2017
  5. Phase I and IND Filed Products, 2017
  6. Discovery and Pre-Clinical Stage Products, 2017
  7. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Monotherapy Products
  8. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Combination Products
  9. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Route of Administration
  10. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Route of Administration
  11. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Molecule Type
  12. Isocitrate Dehydrogenase (IDH1) inhibitors Assessment by Stage and Molecule Type
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll